本页面由Tiger Trade Technology Pte. Ltd.提供服务

Madrigal Pharmaceuticals, Inc.

511.97
-4.7700-0.92%
盘后512.740.7680+0.15%16:29 EDT
成交量:14.55万
成交额:7,449.10万
市值:118.04亿
市盈率:-36.01
高:517.00
开:515.89
低:507.18
收:516.74
52周最高:615.00
52周最低:393.61
股本:2,305.55万
流通股本:1,372.50万
量比:0.55
换手率:1.06%
股息:- -
股息率:- -
每股收益(TTM):-14.2164
每股收益(LYR):-12.8501
净资产收益率:-53.31%
总资产收益率:-17.84%
市净率:22.54
市盈率(LYR):-39.84

数据加载中...

公司资料

公司名字:
Madrigal Pharmaceuticals, Inc.
交易所:
NASDAQ
成立时间:
2016
员工人数:
915
公司地址:
1001 Conshohocken State Road,Suite 2-350,West Conshohocken,Pennsylvania,United States
邮编:
19428
电话:
传真:
- -
简介:
Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营。该公司是一家生物制药公司,专注于为代谢功能障碍相关脂肪性肝炎提供新的治疗方法。脂肪性肝炎是一种严重的肝病,其医疗需求高度未得到满足,可导致肝硬化、肝衰竭、癌症、肝移植需求和过早死亡。该公司的药物Rezifra是一种每日一次的口服肝脏导向甲状腺激素受体β激动剂,旨在针对MASH的关键潜在原因。

董事

名称
职位
Bill Sibold
President and Chief Executive Officer and Director
Julian C. Baker
Independent Chairman of the Board and Independent Director
Jacqualyn A. Fouse
Independent Director
James Daly
Independent Director
Kenneth M. Bate
Independent Director
Paul A. Friedman
Independent Director
Raymond Cheong
Independent Director
Richard S. Levy
Independent Director
Rebecca Taub
Director

股东

名称
职位
Bill Sibold
President and Chief Executive Officer and Director
Mardi Dier
Executive Vice President and Chief Financial Officer
Rita Thakkar
Senior Vice President and Chief Accounting Officer
Carole Huntsman
Executive Vice President and Chief Commercial Officer
David Soergel
Executive Vice President and Chief Medical Officer
Shannon Kelley
Executive Vice President and Chief Legal Counsel